Acceptability Archives - Page 2 of 2

Home
/
Projects
/

Acceptability

Acceptability refers to meeting the policymakers, end-users, and health system requirements for a new TB vaccine for adults and adolescents. This includes defining values from various populations, engaging communities as partners in decision-making, and having robust communication strategies in place. This follows from the WHO global framework for country introduction of new adolescent and adult TB vaccines (https://www.who.int/publications/m/item/who-global-framework-to-prepare-for-country-introduction-of-new-tb-vaccines-for-adults-and-adolescents)

Formative work to understand factors affecting future TB vaccines acceptance and readiness

2023-2027

Hypothetical vaccines

Ongoing

This project aims to collect data to: 1) Assess health facility and health systems readiness for a new TB vaccine, and 2) Explore decision-making factors for new TB vaccine demand and acceptance

Foster political, advocacy for TB vaccines R&D, and enhanced community engagement

2023

Planned

TB vaccine advocacy fellowship

2023

Completed

An urgent call for increased global investment and political support for TB vaccine R&D. With the United Nations High-Level Meeting on TB taking place on 22 September 2023, this call will play an important part in amplifying the voices of the global TB community in demanding new TB vaccines. This letter is also in direct support of the recently launched call to action ‘Deadly Divide: Priorities to Close the Deadly Divide’ from the Stop TB Partnership community and non-governmental organization delegations.

Lessons from a decade of adult vaccine rollout in low- and middle-income countries: A scoping review

2023

Ongoing

This paper synthesizes the insights and lessons learned from different vaccine introductions among adult populations in LMICs from the last decade (i.e., 2013 to 2023).

Bridging the gap: evaluating high TB burden country data needs to support the potential introduction of TB vaccines for adolescents and adults: a workshop report

2024

Completed

A workshop to asked high TB burden country experts about what epidemiological, impact, feasibility and acceptability data they anticipated they would need to guide TB vaccine introduction.

ACEITar: Evaluation of the acceptability of new and repurposed tuberculosis vaccines in Mozambique

2022-2024

BCG revaccination, Hypothetical vaccines

Ongoing

This is a mixed-methods study collecting information on willingness to receive a new TB vaccine among adolescents, their caretakers, and adults in Mozambique, a high TB burden country, to assess potential barriers to high uptake of new TB vaccines.

Potential implementation strategies, acceptability, and feasibility of new and repurposed TB vaccines

2022

BCG revaccination, M72/AS01e

Completed

Our study provides crucial information for implementing novel TB vaccines in specific target groups and on country specific acceptability and feasibility. Key groups for vaccine implementation in these settings were identified, and should be included in clinical trials and implementation planning.

Mapping the existing body of knowledge on new and repurposed TB vaccine implementation: A scoping review

2024

BCG revaccination, Hypothetical vaccines, M72/AS01e

Completed

By synthesizing the existing body of knowledge, this review offers comprehensive insights into the current state of research on implementation of these TB adults and adolescent vaccines. Offering insights into key dimensions: (1) epidemiological impact, (2) costing, cost-effectiveness, and/or economic impact, (3) acceptability, and the (4) feasibility of implementation; this includes implementation strategies of target populations, and health system capabilities.

What do people want?

2024

Hypothetical vaccines

Planned

Investigate current TB prevention modalities vs vaccine. We lack understanding of preferences and trade offs people would be willing to make across a spectrum of issues related to study design, type of vaccines, how they are given, how often, where they are given, to whom, efficacy estimates and side effects etc.